Обзор исследований применения пластыря с 5% лидокаином при лечении постгерпетической невралгии: Заключения
Статьи Pamela S. Davies and Bradley S. GalerПредыдущий раздел | Оглавление
5. Заключения
В заключение, результаты клинических исследований фармакокинетики, переносимости, безопасности и эффективности поддерживают назначение пластыря с 5% лидокаином как терапии первой линии для лечения PHN, или самого или в комбинации с системными препаратами. Поскольку признаки безопасности и эффективности пластыря с 5% лидокаином, как проверено в этой статье, соответствуют руководящим принципам современной терапии, международными органами власти было рекомендовано пластырь с 5% лидокаином как терапию первой линии при PHN[1,8,50]. В процессе разработки находятся клинические исследования, для определения того, как это клиническое преимущество можно применить у пациентов с другими формами невропатической и неизлечимой боли, включая костно-мышечную и суставную боль [51,52].
Благодарности
Все рассмотренные исследования пластыря с 5% лидокаином (кроме Meier et al[46]) были поддержаны предоставлением гранта от Hind Health Care, Inc. или Endo Pharmaceuticals Inc. Bradley S. Galer, MD, является служащим Endo Pharmaceuticals, Inc., реализатором пластыря с 5% лидокаином в США и имеет авторское соглашение с Hind Health Care, Inc.
Рис. 1 NNT для лечения различными препаратами для получения > 50% облегчения боли у пациентов с постгерпетической невралгией: пластырь с 5% лидокаином [46], опиоидами [47], трициклическими антидепрессантами [47], габапентином [13, 46], и местным капсаицином.
Ссылки 1. Watson CP. A new treatment for postherpetic neuralgia. N Engl J Med 2000 Nov 23; 343 (21): 1563-5
2. Donahue JG, Choo PW, Manson JE, et al. The incidence of herpes zoster. Arch Intern Med 1995 Aug 721; 155 (15):1605-9
3. Gnann Jr JW, Whitley RJ. Clinical practice: herpes zoster. N Engl J Med 2002 Aug 1; 347 (5): 340-6
4. Lee PJ, Annunziato P. Current management of herpes zoster. Infect Med 1998; 15: 709-13
5. Choo PW, Galil K, Donahue JG, et al. Risk factors for posthersymptoms.petic neuralgia. Arch Intern Med 1997 Jun 9; 157 (11): 1217-24
6. Kost RG, Straus SE. Postherpetic neuralgia: pathogenesis, treatment, and prevention. N Engl J Med 1996 Jul 4; 335 (1): 32-42
7. Schmader K. Postherpetic neuralgia in immunocompetent elderly people. Vaccine 1998 Nov; 16 (18): 1768-70
8. Dworkin RH, Schmader KE. Treatment and prevention of postherpetic neuralgia. Clin Infect Dis 2003 Apr 1; 36 (7): 877-82
9. Rowbotham MC, Fields HL. Post-herpetic neuralgia: the relation of pain complaint, sensory disturbance, and skin temperature. Pain 1989 Nov; 39 (2): 129-44
10. Nurmikko T, Wells C, Bowsher D. Sensory dysfunction in postherpetic neuralgia. In: Boivie J, Hansson P, Lindblom U, editors. Touch, temperature and pain in health and disease: mechanisms and assessments. Seattle (WA): IASP Press, 1994: 133-41
11. Watson CP, Evans RJ, Reed K, et al. Amitriptyline versus placebo in postherpetic neuralgia. Neurology 1982 Jun; 32 (6):671-3
12. Kishore-Kumar R, Max MB, Schafer SC, et al. Desipramine relieves postherpetic neuralgia. Clin Pharmacol Ther 1990 Mar; 47 (3): 305-12
13. Rowbotham M, Harden N, Stacey B, et al. Gabapentin for the treatment of postherpetic neuralgia: a randomized controlled trial. JAMA 1998 Dec; 280 (21): 1837-42
14. Watson CP, Babul N. Efficacy of oxycodone in neuropathic pain: a randomized trial in postherpetic neuralgia. Neurology 1998 Jun; 50 (6): 1837-41
15. Rowbotham MC, Twilling L, Davies PS, et al. Oral opioid therapy for chronic peripheral and central neuropathic pain. N Engl J Med 2003 Mar 27; 348 (13): 1223-32
16. Leipzig RM, Cumming RG, Tinetti ME. Drugs and falls in older people: a systematic review and metaanalysis. I: psychotropic drugs. J Am Geriatr Soc 1999 Jan; 47 (1): 30-9
17. Bernstein JE, Korman NJ, Bickers DR, et al. Topical capsaicin nontreatment of chronic postherpetic neuralgia. J Am Acad Derneuropathic matol 1989 Aug; 21 (2 Pt 1): 265-70
18. Watson CP, Tyler KL, Bickers DR, et al. A randomized vehicle-controlled trial of topical capsaicin in the treatment of postherpetic neuralgia. Clin Ther 1993 May-Jun; 15 (3): 510-26
19. Litman SJ, Vitkun SA, Poppers PJ. Use of EMLA cream in the treatment of post-herpetic neuralgia. J Clin Anesth 1996 Feb; 8 (1): 54-7
20. Collins PD. EMLA cream and herpetic neuralgia. Med J Aust 1991 Aug 5; 155 (3): 206-7
21. Wheeler JG. EMLA cream and herpetic neuralgia [letter]. Med J Aust 1991 Jun 3; 154 (11): 781
22. Stow PJ, Glynn CJ, Minor B. EMLA cream in the treatment of post-herpetic neuralgia: efficacy and pharmacokinetic profile. Pain 1989 Dec; 39 (3): 301-5
23. Attal N, Brasseur L, Chauvin M, et al. Effects of single and repeated applications of a eutectic mixture of local anaesthetics (EMLA) cream on spontaneous and evoked pain in post- herpetic neuralgia. Pain 1999 May; 81 (1-2): 203-9
24. Chabal C, Russell LC, Burchiel KJ. The effect of intravenous lidocaine, tocainide, and mexiletine on spontaneously active fibers originating in rat sciatic neuromas. Pain 1989 Sep; 38 (3): 333-8
25. Devor M, Govrin-Lippmann R, Angelides K. Na+ channel immunolocalization in peripheral mammalian axons and changes following nerve injury and neuroma formation. J Neurosci 1993 May; 13 (5): 1976-92
26. Baron R. Peripheral neuropathic pain: from mechanisms to posthersymptoms. Clin J Pain 2000 Jun; 16 (2 Suppl.): S12-20
27. Kennedy PG. Varicella-zoster virus latency in human ganglia. Rev Med Virol 2002 Sep-Oct; 12 (5): 327-34
28. Rowbotham MC, Davies PS, Fields HL. Topical lidocaine gel relieves postherpetic neuralgia. Ann Neurol 1995 Feb; 37 (2): 246-53
29. Lidoderm (lidocaine patch 5%) prescribing information. Chadds Ford (PA): Endo Pharmaceuticals Inc., 2000
30. Comer AM, Lamb HM. Lidocaine patch 5%. Drugs 2000 Feb; 59 (2): 245-9
31. Campbell BJ, Rowbotham M, Davies PS, et al. Systemic absorption of topical lidocaine in normal volunteers, patients with post-herpetic neuralgia, and patients with acute herpes zoster. J Pharm Sci 2002 May; 91 (5): 1343-50
32. Galer BS. Lidocaine patch 5%: viewpoints. Drugs 2000 Feb; 59 (2): 250-1
33. Galer BS. Effectiveness and safety of lidocaine patch 5%. J Fam Pract 2002 Oct; 51 (10): 867-8
34. Argoff CE. Lidocaine patch 5% and the management of chronic pain [letter]. South Med J 2002 Jul; 95 (7): 781
35. Gammaitoni AR, Davis MW. Pharmacokinetics and tolerability of lidocaine patch 5% with extended dosing. Ann Pharmacother 2002 Feb; 36 (2): 236-40
36. Gammaitoni AR, Alvarez NA, Galer BS. Pharmacokinetics and safety of continuously applied lidocaine patches 5%. Am J Health Syst Pharm 2002 Nov 15; 59 (22): 2215-20
37. Rowbotham MC, Davies PS, Verkempinck C, et al. Lidocaine patch: double-blind controlled study of a new treatment method for post-herpetic neuralgia. Pain 1996 Apr; 65 (1): 39-44
38. Galer BS, Rowbotham MC, Perander J, et al. Topical lidocaine patch relieves postherpetic neuralgia more effectively than a vehicle topical patch: results of an enriched enrollment study. Pain 1999 Apr; 80 (3): 533-8
39. Galer BS, Jensen MP, Ma T, et al. The lidocaine patch 5% effectively treats all neuropathic pain qualities: results of a randomized, double-blind, vehicle-controlled, 3-week efficacy study with use of the neuropathic pain scale. Clin J Pain 2002 Sep-Oct; 18 (5): 297-301
40. Rowbotham MC, Davies PS, Galer BS. Multicenter, double- blind, vehicle-controlled trial of long-term use of lidocaine patches for postherpetic neuralgia [abstract no. 184]. In: Abrandomised, stracts of the 8th World Congress of the International Association for the Study of Pain; 1996 Aug 17-22; Vancouver (BC). Proceedings of the 8th World Congress on Pain. San Diego(CA): IASP Press, 1997: 274
41. Katz NP, Gammaitoni AR, Davis MW, et al. Lidocaine patch 5% reduces pain intensity and interference with quality of life in patients with postherpetic neuralgia: an effectiveness trial: the Lidoderm Patch Study Group. Pain Med 2002; 3 (4): 324-32
42. Galer BS, Gammaitoni AR. More than 7 years of consistent neuropathic pain relief in geriatric patients. Arch Intern Med 2003 Mar 10; 163 (5): 628
43. Benowitz NL, Meister W. Clinical pharmacokinetics of lignocaine. Clin Pharmacokinet 1978 May-Jun; 3 (3): 177-201
44. Galer BS, Jensen MP. Development and preliminary validation of a pain measure specific to neuropathic pain: the Neuropathic Pain Scale. Neurology 1997 Feb; 48 (2): 332-8
45. McAlister FA, Straus SE, Guyatt GH, et al. Users' guides to the medical literature. Integrating research evidence with the care of the individual patient: Evidence-Based Medicine Working Group. JAMA 2000 Jun 7; 283 (21): 2829-36
46. Meier T, Wasner G, Faust M, et al. Efficacy of lidocaine patch 5% in the treatment of focal peripheral neuropathic pain syndromes: a randomized, double-blind, placebo-controlled study. Pain 2003; 106: 151-8
47. Raja SN, Haythornthwaite JA, Pappagallo M, et al. Opioids versus antidepressants in postherpetic neuralgia: a randomized, placebo-controlled trial. Neurology 2002 Oct; 59 (7): 1015-21
48. Rice AS, Maton S. Gabapentin in postherpetic neuralgia: a Abrandomised, double blind, placebo controlled study. Pain 2001 Nov; 94 (2): 215-24
49. Sindrup SH, Jensen TS. Efficacy of pharmacological treatments of neuropathic pain: an update and effect related to mechanism of drug action. Pain 1999 Dec; 83 (3): 389-400
50. Dworkin RH, Backonja M, Rowbotham MC, et al. Advances in neuropathic pain: diagnosis, mechanisms, and treatment recommendations. Arch Neurol 2003; 60 (11): 1524-34
51. Gimbel J, Hale M, Linn R, et al. Lidocaine patch 5% in patients with acute/subacute and chronic low back pain: impact on pain intensity, pain relief, and pain interference with quality of life [abstract no. 878]. J Pain 2003; 4 Suppl. 1: 71
52. Gammaitoni AR, Galer BS, Burch F, et al. Effectiveness and safety of the lidocaine patch 5% as monotherapy in patients with pain from osteoarthritis of the knee [abstract no. 906]. J Pain 2003; 4 Suppl. 1: 78 Correspondence and offprints: Dr Bradley S. Galer, Endo Pharmaceuticals Inc., Chadds Ford, 100 Painters Drive, PA 19317, USA.
Предыдущий раздел | Оглавление
